Clinical Trial

Molecular Endotypes of Chronic Idiopathic Urticaria

Active, Not Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated August 15, 2024 (before its estimated March 2025 completion). Its status may not reflect the trial's current state.
Summary
This study plans to learn more about why some people with Chronic Idiopathic Urticaria (CIU) respond to treatment with omalizumab (Xolair). It will test people before they receive treatment with omalizumab as part of standard of care, to see if there are differences in their blood and skin that can predict who responds to treatment.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2021-02-26; most recent amendment 2024-08-13.
Status change: Recruiting → Active, Not Recruiting 2024-08-13
Status change: Not Yet Recruiting → Recruiting 2022-01-18
Trial Details
NCT Number NCT04774315
Lead Sponsor University of Colorado, Denver
Conditions Chronic Urticaria, Idiopathic
Enrollment 15 participants
Start Date 2022-01-01
Primary Completion 2025-03 (estimated)
Study Completion 2025-03 (estimated)
Updated on ClinicalTrials.gov 2024-08-15